New agents in post-remission therapy

The choice of post-remission therapy for patients with acute myeloid leukemia (AML) depends on age, response to initial therapy, and on disease-related biology. High-dose ara-C (HIDAC) is the standard chemotherapy-based post-remission treatment for younger AML patients, but diagnostic cytogenetics and genetic features may mandate an allogeneic stem cell transplant. While intensive chemotherapy has little utility, the optimal post-remission therapy for older adults remains unclear, though reduced-intensity conditioning allogeneic stem cell transplant is being used with increasing frequency.